Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
As of close of business last night, Regeneron Pharmaceuticals, Inc’s stock clocked out at $784.61, down -0.34% from its previous closing price of $787.32. In other words, the price has decreased by -$0.34 from its previous closing price. On the day, 0.87 million shares were traded. REGN stock price reached its highest trading level at $790.98 during the session, while it also had its lowest trading level at $777.0.
Ratios:
To gain a deeper understanding of REGN’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.76 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 19.53. For the most recent quarter (mrq), Quick Ratio is recorded 3.33 and its Current Ratio is at 4.06. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.09.
On November 24, 2025, HSBC Securities started tracking the stock assigning a Buy rating and target price of $255.
On November 13, 2025, Scotiabank started tracking the stock assigning a Sector Perform rating and target price of $650.Scotiabank initiated its Sector Perform rating on November 13, 2025, with a $650 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 20 ’25 when Bassler Bonnie L sold 760 shares for $750.00 per share. The transaction valued at 570,000 led to the insider holds 1,548 shares of the business.
Bassler Bonnie L bought 760 shares of REGN for $570,000 on Nov 20 ’25. On Nov 07 ’25, another insider, Pitofsky Jason, who serves as the VP Controller of the company, sold 431 shares for $651.43 each. As a result, the insider received 280,766 and left with 4,233 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, REGN now has a Market Capitalization of 83158802432 and an Enterprise Value of 74762469376. As of this moment, Regeneron’s Price-to-Earnings (P/E) ratio for their current fiscal year is 18.78, and their Forward P/E ratio for the next fiscal year is 18.07. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.43. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.79 while its Price-to-Book (P/B) ratio in mrq is 2.67. Its current Enterprise Value per Revenue stands at 5.247 whereas that against EBITDA is 17.195.
Stock Price History:
The Beta on a monthly basis for REGN is 0.34, which has changed by 0.045839906 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, REGN has reached a high of $800.99, while it has fallen to a 52-week low of $476.49. The 50-Day Moving Average of the stock is 25.08%, while the 200-Day Moving Average is calculated to be 31.39%.
Shares Statistics:
It appears that REGN traded 1.10M shares on average per day over the past three months and 1364900 shares per day over the past ten days. A total of 103.50M shares are outstanding, with a floating share count of 101.19M. Insiders hold about 3.72% of the company’s shares, while institutions hold 85.43% stake in the company. Shares short for REGN as of 1763078400 were 2844265 with a Short Ratio of 2.58, compared to 1760486400 on 2927169. Therefore, it implies a Short% of Shares Outstanding of 2844265 and a Short% of Float of 2.86.
Earnings Estimates
The market rating for Regeneron Pharmaceuticals, Inc (REGN) is a result of the insights provided by 20.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $10.41, with high estimates of $11.39 and low estimates of $8.95.
Analysts are recommending an EPS of between $45.85 and $39.78 for the fiscal current year, implying an average EPS of $43.22. EPS for the following year is $37.38, with 9.0 analysts recommending between $44.9 and $29.56.
Revenue Estimates
In. The current quarter, 20 analysts expect revenue to total $3.75B. It ranges from a high estimate of $4.11B to a low estimate of $3.39B. As of. The current estimate, Regeneron Pharmaceuticals, Inc’s year-ago sales were $3.79BFor the next quarter, 20 analysts are estimating revenue of $3.42B. There is a high estimate of $3.78B for the next quarter, whereas the lowest estimate is $3.17B.
A total of 26 analysts have provided revenue estimates for REGN’s current fiscal year. The highest revenue estimate was $14.57B, while the lowest revenue estimate was $13.85B, resulting in an average revenue estimate of $14.19B. In the same quarter a year ago, actual revenue was $14.2BBased on 25 analysts’ estimates, the company’s revenue will be $14.95B in the next fiscal year. The high estimate is $16.51B and the low estimate is $13.33B.
